Many mitochondria (green) show reduced membrane potential (indicated by the potentiometric reporter TMRM, red) in fibroblasts lacking MFN2.Mourier et al. reveal that the mitochondrial fusion protein Mitofusin 2 (MFN2) is required to maintain production of the respiratory chain cofactor coenzyme Q.

The closely related GTPases MFN1 and MFN2 are both required for mitochondrial outer membrane fusion. *Mfn1*-deficient mice nevertheless seem perfectly healthy, but mice lacking *Mfn2* die soon after birth. Moreover, only *Mfn2* has been linked to human diseases, including the peripheral neuropathy Charcot-Marie-Tooth type 2A. Mourier et al. therefore investigated whether loss of *Mfn2* affects mitochondrial function in other ways besides membrane fusion.

The researchers found that mitochondrial respiration and ATP production was impaired in *Mfn2*-deficient cardiomyocytes compared with wild-type and *Mfn1*-deficient cells. The levels and activities of individual respiratory chain protein complexes were unaltered in mitochondria lacking *Mfn2*, but the levels of coenzyme Q, an electron carrier that transfers electrons to respiratory chain complex III, were strongly reduced. Supplementing *Mfn2*-null cells with coenzyme Q partially restored respiratory chain function.

Coenzyme Q is synthesized from organic intermediates generated by the terpenoid biosynthetic pathway. Mourier et al. found that many of the enzymes and metabolites involved in this pathway were down-regulated in the absence of MFN2. Senior author Nils-Göran Larsson now wants to investigate how MFN2 regulates terpenoid synthesis. Because this pathway takes place across multiple subcellular compartments, one possibility is that MFN2 mediates mitochondrial contacts with other organelles. Larsson also hopes that coenzyme Q supplements could help treat patients with diseases caused by mutations in *Mfn2*.
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